| Literature DB >> 29601602 |
Hyun-Jung Lee1, Eue-Keun Choi1, Seung-Hwan Lee2, Yong-Jin Kim1, Kyung-Do Han3, Seil Oh1.
Abstract
BACKGROUND: Whether metabolically healthy obese (MHO) individuals are at increased risk of ischemic stroke is not well known. We investigated the association of the MHO phenotype with ischemic stroke.Entities:
Mesh:
Year: 2018 PMID: 29601602 PMCID: PMC5877885 DOI: 10.1371/journal.pone.0195210
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of the study population.
| Total(n = 354,083) | MHNW (n = 110,531, 31.2%) | MUNW (n = 130,583, 36.9%) | MHO (n = 26,448, 7.5%) | MUO (n = 86,521, 24.4%) | |
|---|---|---|---|---|---|
| Male sex, n (%) | 186,563 (52.7%) | 46,599 (42.2%) | 72,758 (55.7%) | 15,395 (58.2%) | 51,811 (59.9%) |
| Age, years | 45.8 ± 14.2 | 39.1 ± 12.2 | 49.7 ± 14.5 | 41.7 ± 11.7 | 49.8 ± 13.4 |
| Body mass index, kg/m2 | 23.8 ± 3.0 | 21.8 ± 1.7 | 22.5 ± 1.6 | 26.9 ± 1.8 | 27.4 ± 2.2 |
| Elevated blood pressure | 146,622 (41.4%) | 83,920 (64.3%) | 62,702 (72.5%) | ||
| Elevated fasting glucose | 98,735 (27.9%) | 58,419 (44.7%) | 40,316 (46.6%) | ||
| Elevated total cholesterol | 37,790 (10.7%) | 20,514 (15.7%) | 17,276 (20.0%) | ||
| Hypertension | 52,487 (14.8%) | 26,852 (20.6%) | 25,635 (29.6%) | ||
| Diabetes mellitus | 16,332 (4.6%) | 8,590 (6.6%) | 7,742 (8.9%) | ||
| Dyslipidemia | 34,116 (9.6%) | 18,613 (14.3%) | 15,503 (17.9%) | ||
| Ischemic heart disease | 10,246 (2.9%) | 488 (0.4%) | 5,069 (3.9%) | 167 (0.6%) | 4,522 (5.2%) |
| Peripheral artery disease | 8,421 (2.4%) | 555 (0.5%) | 4,203 (3.2%) | 181 (0.7%) | 3,482 (4.0%) |
| Congestive heart failure | 4,635 (1.3%) | 392 (0.4%) | 2,144 (1.6%) | 135 (0.5%) | 1,964 (2.3%) |
| Transient ischemic attack | 1,435 (0.4%) | 133 (0.1%) | 663 (0.5%) | 43 (0.2%) | 596 (0.7%) |
| Venous thromboembolism | 63 (0.0%) | 5 (0.0%) | 34 (0.0%) | 4 (0.0%) | 20 (0.0%) |
| End-stage renal disease | 109 (0.0%) | 5 (0.0%) | 77 (0.1%) | 0 (0.0%) | 27 (0.0%) |
| Liver cirrhosis | 754 (0.2%) | 102 (0.1%) | 399 (0.3%) | 41 (0.2%) | 212 (0.2%) |
| Chronic obstructive pulmonary disease | 18,744 (5.3%) | 4,042 (3.7%) | 8,337 (6.4%) | 980 (3.7%) | 5,415 (6.3%) |
| Cancer | 4,757 (1.3%) | 965 (0.9%) | 2,243 (1.7%) | 233 (0.9%) | 1,316 (1.6%) |
| Cardiac surgery | 157 (0.0%) | 9 (0.0%) | 98 (0.1%) | 3 (0.0%) | 47 (0.1%) |
| Smoking | |||||
| Non-smoker | 241,159 (68.1%) | 79,800 (72.2%) | 87,556 (67.1%) | 16,871 (63.8%) | 56,932 (65.8%) |
| Ex-smoker | 18,470 (5.2%) | 4,354 (3.9%) | 7,058 (5.4%) | 1,457 (5.5%) | 5,601 (6.5%) |
| Current-smoker | 94,454 (26.7%) | 26,377 (23.9%) | 35,969 (27.5%) | 8,120 (30.7%) | 23,988 (27.7%) |
| Drinking | |||||
| Non-drinker | 185,788 (52.5%) | 57,771 (52.3%) | 70,104 (53.7%) | 13,009 (49.2%) | 44,904 (51.9%) |
| 2–3 times per month | 65,693 (18.6%) | 25,528 (23.1%) | 21,000 (16.1%) | 5,545 (21.0%) | 13,620 (15.7%) |
| ≥ 1 time per week | 102,602 (29.0%) | 27,232 (24.6%) | 39,479 (30.2%) | 7,894 (29.8%) | 27,997 (32.4%) |
| Exercise | |||||
| None | 193,463 (54.6%) | 63,808 (57.7%) | 71,533 (54.8%) | 13,494 (51.0%) | 44,628 (51.6%) |
| 1–4 times per week | 131,245 (37.1%) | 39,896 (36.1%) | 46,766 (35.8%) | 10,965 (41.5%) | 33,618 (38.9%) |
| ≥ 5 times per week | 29,375 (8.3%) | 6,827 (6.2%) | 12,284 (9.4%) | 1,989 (7.5%) | 8,275 (9.6%) |
| Low income (Lowest 20 percentile) | 54,983 (15.5%) | 17,313 (15.7%) | 20,951 (16.0%) | 3,867 (14.6%) | 12,852 (14.9%) |
| Rural area | 190,202 (53.7%) | 57,071 (51.6%) | 71,154 (54.5%) | 14,265 (53.9%) | 47,712 (55.1%) |
| Obesity | 112,969 (31.9%) | ||||
| BMI 25–29.9 kg/m2 | 101,657 (28.7%) | 24,861 (94.0%) | 76,796 (88.8%) | ||
| BMI ≥ 30 kg/m2 | 11,312 (3.2%) | 1,587 (6.0%) | 9,725 (11.2%) | ||
| Metabolically unhealthy | 217,104 (61.3%) | ||||
| Number of MetS criteria | |||||
| 1 | 83,399 (63.9%) | 44,091 (51.0%) | |||
| 2 | 38,102 (29.2%) | 31,576 (36.5%) | |||
| 3 | 9,082 (7.0%) | 10,854 (12.5%) | |||
| Mean follow-up duration, years | 7.43 ± 1.52 | 7.45 ± 1.48 | 7.44 ± 1.54 | 7.45 ± 1.48 | 7.38 ± 1.55 |
MHNW = metabolically healthy normal weight; MUNW = metabolically unhealthy normal weight; MHO = metabolically healthy obese; MUO = metabolically unhealthy obese; BMI = body mass index; MetS = metabolic syndrome
* SBP ≥ 130 and/or DBP ≥ 85 mmHg;
† Fasting glucose ≥ 100 mg/dL;
‡ Total cholesterol ≥ 240 mg/dL
Fig 1Kaplan-Meier curves showing the incidence of ischemic stroke according to groups categorized by obesity and metabolic health.
MHNW = metabolically healthy normal weight; MUNW = metabolically unhealthy normal weight; MHO = metabolically healthy obese; MUO = metabolically unhealthy obese. P-value for comparison by log-rank test.
Incidence and risk of ischemic stroke according to groups divided by obesity and metabolic health.
| MHNW (n = 110,531) | MUNW (n = 130,583) | MHO (n = 26,448) | MUO (n = 86,521) | |
|---|---|---|---|---|
| Stroke cases, n (%) | 465 (0.4%) | 2,535 (1.9%) | 121 (0.5%) | 1,763 (2.0%) |
| Stroke incidence (per 1,000 person-years) | 0.56 | 2.61 | 0.61 | 2.76 |
| Hazard ratio (HR) | ||||
| Crude | 1 (ref) | 4.62 (4.19–5.10) | 1.09 (0.89–1.33) | 4.90 (4.42–5.42) |
| Adjusted | 1 (ref) | 1.72 (1.55–1.90) | 0.99 (0.81–1.20) | 2.06 (1.85–2.28) |
| Age < 50 | 1 (ref) | 1.57 (1.25–1.95) | 1.01 (0.70–1.46) | 2.38 (1.90–2.97) |
| Age ≥ 50 | 1 (ref) | 1.64 (1.46–1.84) | 0.94 (0.74–1.20) | 1.87 (1.66–2.10) |
† Unadjusted crude hazard ratio (HR) and 95% confidence interval (CI);
‡ Adjusted for age, sex, income, area, smoking, drinking, exercise, history of ischemic heart disease, peripheral artery disease, congestive heart failure, transient ischemic attack, venous thromboembolism, chronic obstructive pulmonary disease, end-stage renal disease, liver cirrhosis, cancer, and cardiac surgery
The association of obesity, metabolic health components, and metabolic health status with ischemic stroke.
| N | Stroke cases | Model 1 | Model 2 | Model 3 | |
|---|---|---|---|---|---|
| Obesity | |||||
| Normal weight | 241,114 | 3,000 (1.2%) | 1 (reference) | 1 (reference) | |
| Obese | 112,969 | 1,884 (1.7%) | 1.25 (1.18–1.32) | 1.16 (1.09–1.23) | |
| Stage I obesity (BMI 25–29.9 kg/m2) | 101,657 | 1,700 (1.7%) | 1.24 (1.17–1.31) | 1.15 (1.09–1.23) | |
| Stage II obesity (BMI ≥ 30 kg/m2) | 11,312 | 184 (1.6%) | 1.37 (1.18–1.59) | 1.21 (1.04–1.41) | |
| Metabolic health components (MetS criteria) | |||||
| Elevated blood pressure or treatment for hypertension | 161,450 | 3,784 (2.3%) | 1.78 (1.66–1.91) | 1.74 (1.62–1.86) | |
| Elevated glucose or treatment for diabetes mellitus | 101,374 | 2,314 (2.3%) | 1.25 (1.18–1.33) | 1.24 (1.17–1.32) | |
| Elevated total cholesterol or treatment for dyslipidemia | 63,830 | 1,567 (2.5%) | 1.23 (1.15–1.31) | 1.22 (1.14–1.30) | |
| Metabolic health status | |||||
| Healthy (0 MetS criteria) | 136,979 | 586 (0.4%) | 1 (reference) | 1 (reference) | |
| Unhealthy (≥1 MetS criteria) | 217,104 | 4,884 (1.4%) | 1.86 (1.70–2.03) | 1.80 (1.65–1.97) |
HR = Hazard ratio; CI = Confidence interval; BMI = body mass index; MetS = metabolic syndrome
† Adjusted for age, sex, income, area, smoking, drinking, exercise, history of ischemic heart disease, peripheral artery disease, congestive heart failure, transient ischemic attack, venous thromboembolism, chronic obstructive pulmonary disease, end-stage renal disease, liver cirrhosis, cancer, and cardiac surgery;
‡ Further adjustment for metabolic health components;
§ Further adjustment for obesity
Fig 2Risk for ischemic stroke according to BMI.
BMI = body mass index. Each point representing hazard ratios (HRs) with error bars for 95% confidence intervals (95% CI). Asterisks indicated significant difference with reference group.
Fig 3Number of metabolic syndrome risk factors according to BMI intervals.
MetS = Metabolic syndrome; BMI = body mass index.
The association of metabolic health status with ischemic stroke stratified by body mass index groups.
| N | Stroke cases | HR (95% CI) | |
|---|---|---|---|
| Normal weight (BMI 18.5–24.9 kg/m2) | |||
| Metabolically healthy | 110,531 | 465 (0.4%) | 1 (reference) |
| Metabolically unhealthy | 130,583 | 2,535 (1.9%) | 1.68 (1.52–1.87) |
| Obese (BMI ≥ 25 kg/m2) | |||
| Metabolically healthy | 26,448 | 121 (0.5%) | 1 (reference) |
| Metabolically unhealthy | 86,521 | 1,763 (2.0%) | 2.16 (1.79–2.60) |
| Stage I obesity (BMI 25–29.9 kg/m2) | |||
| Metabolically healthy | 24,861 | 115 (0.5%) | 1 (reference) |
| Metabolically unhealthy | 76,796 | 1,585 (2.1%) | 2.13 (1.76–2.59) |
| Stage II obesity (BMI ≥ 30 kg/m2) | |||
| Metabolically healthy | 1,587 | 6 (0.4%) | 1 (reference) |
| Metabolically unhealthy | 9,725 | 178 (1.8%) | 2.32 (1.02–5.29) |
HR = Hazard ratio; CI = Confidence interval; BMI = body mass index
Adjusted for age, sex, income, area, smoking, drinking, exercise, history of ischemic heart disease, peripheral artery disease, congestive heart failure, transient ischemic attack, venous thromboembolism, chronic obstructive pulmonary disease, end-stage renal disease, liver cirrhosis, cancer, and cardiac surgery
The association of obesity with ischemic stroke stratified by metabolic health status.
| N | Stroke cases | HR (95% CI) | |
|---|---|---|---|
| Metabolically healthy | |||
| Normal weight (BMI 18.5–24.9 kg/m2) | 110,531 | 465 (0.4%) | 1 (reference) |
| Obese (BMI ≥ 25 kg/m2) | 26,448 | 121 (0.5%) | 1.00 (0.81–1.22) |
| Stage I obesity (BMI 25–29.9 kg/m2) | 24,861 | 115 (0.5%) | 0.99 (0.81–1.22) |
| Stage II obesity (BMI ≥ 30 kg/m2) | 1,587 | 6 (0.4%) | 1.06 (0.47–2.38) |
| Metabolically unhealthy | |||
| Normal weight (BMI 18.5–24.9 kg/m2) | 130,583 | 2,535 (1.9%) | 1 (reference) |
| Obese (BMI ≥ 25 kg/m2) | 86,521 | 1,763 (2.0%) | 1.19 (1.12–1.27) |
| Stage I obesity (BMI 25–29.9 kg/m2) | 76,796 | 1,585 (2.1%) | 1.18 (1.11–1.26) |
| Stage II obesity (BMI ≥ 30 kg/m2) | 9,725 | 178 (1.8%) | 1.25 (1.07–1.46) |
HR = Hazard ratio; CI = Confidence interval; BMI = body mass index
Adjusted for age, sex, income, area, smoking, drinking, exercise, history of ischemic heart disease, peripheral artery disease, congestive heart failure, transient ischemic attack, venous thromboembolism, chronic obstructive pulmonary disease, end-stage renal disease, liver cirrhosis, cancer, and cardiac surgery